

TITLE OF THE INVENTIONGREEN FLUORESCENT PROTEINS AND BLUE FLUORESCENT
PROTEINSBACKGROUND OF THE INVENTION5 Field of the invention

This invention relates to novel fluorescent proteins, GFPs and BFPs.

Related background art

10 GFP (Green Fluorescent Protein), which was found in *Aequorea victoria*, is a relatively small protein having a molecular weight of 26,900 and comprising the overall 238 amino acid residues as shown below (SEQ No. 1 in the Sequence Listing).

15	Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val			
	1	5	10	15
	Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu			
	20		25	30
	Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys			
20	35	40	45	
	Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe			
	50	55	60	
	Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln			
	70		75	80
25	His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg			
	85		90	95

Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
 100 105 110
 Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
 115 120 125
 5 Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
 130 135 140
 Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
 145 150 155 160
 Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
 10 165 170 175
 Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
 180 185 190
 Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
 195 200 205
 15 Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
 210 215 230
 Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
 225 230 235 238

20 In the present specification, the term "GFP
 protein" refers to a protein that emits green
 fluorescence when excited by ultraviolet-blue light
 and that, then, does not require an energy source
 such as a special substrate or ATP. In other words,
 25 the chromophore formation reaction of GFP is
 autonomous, and the portion of serine-tyrosine-

© 1998, All rights reserved.
TOEFL TEST

glycine at Nos. 65-67 from the amino terminus forms an imidazolidine ring oxidatively which serves as a chromophore. (Yuichiro Watanabe, Gendai Kagaku "Modern Chemistry" 12, 46-52 (1995); R. Heim et al. Proc. Natl. Acad. Sci. USA 91: 12501-12504 (1994).)

Because GFP possesses such a property, a DNA encoding this protein is linked to a suitable expression vector and is introduced into the desired cells to express GFP, which alone results in fluorescent images. Therefore, GFP is in use for the visual analysis of gene expression and localization of proteins in a variety of cells in their viable state. However, since such GFP was not luminous at 37 °C, there was a problem that culturing must necessarily be done at 30 °C for the purpose of observation in mammalian cells or the like. In connection with this problem, it has been reported that the mutations of V163A and S175G enhance the thermal stability. (K. R. Siemering et al. Curr. Biol. 6, 1653-1663 (1996).)

Recently, a mutant of GFP into which the mutations of Y66H and Y145F were introduced and which had different wavelength characteristics (it is also referred to as "Mutant," and its amino acid sequence is described below with the above-mentioned mutations shown as underlined) was developed. This is referred to as "BFP (Blue Fluorescent Protein)," because it

emits blue fluorescence by UV excitation. (R. Heim et al. Curr. Biol. 6, 178-182 (1996); R. Heim et al. Proc. Natl. Acad. Sci. USA 91, 12501-12504 (1994).) In the present specification, the term "BFP protein" 5 refers to a protein that emits blue fluorescence when excited by ultraviolet-blue light and that, then, does not require an energy source such as a special substrate or ATP. However, such BFP had a problem that it experienced severe fading as compared to GFP 10 and was difficult to be observed under a microscope or the like. As used herein to designate mutation, the position of the mutation is expressed by a specific amino acid number in the sequence of the above-mentioned wild type; the amino acid prior to 15 its mutation is described preceding the number and the mutated amino acid is to be described following the number.

Further, amino acids are designated by the one-letter code or three-letter code as appropriate.

20

Met	Ser	Lys	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro	Ile	Leu	Val
1															15
Glu	Leu	Asp	Gly	Asp	Val	Asn	Gly	His	Lys	Phe	Ser	Val	Ser	Gly	Glu
20															30
Gly	Glu	Gly	Asp	Ala	Thr	Tyr	Gly	Lys	Leu	Thr	Leu	Lys	Phe	Ile	Cys
25															
35															45

Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
 50 55 60

Ser His Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln
 66 70 75 80

5 His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
 85 90 95

Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
 100 105 110

Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
 110 115 120 125

Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
 130 135 140

Phe Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
 145 150 155 160

15 Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
 165 170 175

Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
 180 185 190

Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
 195 200 205

Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
 210 215 230

Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
 225 230 235 238

25

SUMMARY OF THE INVENTION

This invention provides novel fluorescent proteins, GFPs and BFPs.

The present invention will become more fully understood from the detailed description given hereinbelow and the accompanying drawings which are given by way of illustration only, and thus are not to be considered as limiting the present invention.

Further scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

In view of the above-mentioned problems, the present inventors made extensive researches and succeeded in the discovery of novel GFPs and BFPs that are free from such problems by introducing certain mutations into specific positions of the amino acid sequence for GFP or BFP, thus accomplishing this invention.

Specifically, according to this invention, GFP mutants or BFP mutants were prepared from GFP or BFP,

PCT/JP2000/00025650

either of which was already known (these may be hereinafter referred to as "wild type"), by introducing certain mutations into its specific positions through various techniques. Then, BFP
5 mutants that still emitted brightly after UV radiation for about one hour were obtained among such mutants. In other words, the invention has solved the problem that the conventional BFP experienced severe fading as compared to GFP and was difficult to
10 be observed under a microscope.

Likewise, a mutant of GFP that was brightly luminous even at 37 °C was obtained. Namely, the invention has solved the problem that because the conventional GFP was not luminous at 37 °C, its
15 observation in mammalian cells and the like necessitated the need to culture them at 30 °C.

Specifically, on the basis of the amino acid sequence for the wild type of GFP (283 amino acid residues, SEQ No. 1 in the Sequence Listing), GFPs
20 into which the mutations as described below had been introduced were prepared, and their fluorescence and thermal characteristics were investigated in this invention.

- (1) Phe64Leu
- 25 (2) Val163Ala and Ser175Gly were introduced.
- (3) Phe64Leu, Val163Ala and Ser175Gly were introduced.

Furthermore, on the basis of the amino acid sequence for the wild type of BFP as described above, GFPS into which the mutations as described below had been introduced were prepared, and their fluorescence and thermal characteristics were investigated in this invention. Here, the mutations introduced were based 5 on the amino acid sequence for the wild type of GFP.

- (4) Y66H, Y145F: Phe64Leu, Leu236Arg
10 (5) Y66H, Y145F: Phe64Leu
(6) Y66H, Y145F: Val163Ala, Ser175Gly
(7) Y66H, Y145F: Phe64Leu, Val163Ala, Ser175Gly, Leu236Arg

Consequently, it was discovered that the resulting BFP and GFP mutants had improved fluorescence characteristics and thermal stability. Specifically, this invention provides novel BFPs and 15 GFPS as will be described below, and further, genes coding them.

20 1. A GFP protein comprising the amino acid sequence set forth in SEQ ID No. 1 in the Sequence Listing, said sequence having at least mutations of Phe64Leu, Val163Ala, and Ser175Gly.

25 2. A GFP protein comprising the amino acid sequence set forth in SEQ ID No. 1 in the Sequence Listing, said sequence having the three mutations of Phe64Leu, Val163Ala, and Ser175Gly.

3. A BFP protein comprising the amino acid

sequence set forth in SEQ ID No. 1 in the Sequence Listing, said sequence having at least mutations of Y66H, Y145F, and Phe64Leu.

5 4. A BFP protein comprising the amino acid sequence set forth in SEQ ID No. 1 in the Sequence Listing, said sequence having at least mutations of Y66H, Y145F, Phe64Leu, and Leu236Arg.

10 5. A BFP protein comprising the amino acid sequence set forth in SEQ ID No. 1 in the Sequence Listing, said sequence having the four mutations of Y66H, Y145F, Phe64Leu, and Leu236Arg.

15 6. A BFP protein comprising the amino acid sequence set forth in SEQ ID No. 1 in the Sequence Listing, said sequence having at least mutations of Y66H, Y145F, Phe64Leu, Val163Ala, Ser175Gly and Leu236Arg.

20 7. A BFP protein comprising the amino acid sequence set forth in SEQ ID No. 1 in the Sequence Listing, said sequence having the six mutations of Y66H, Y145F, Phe64Leu, Val163Ala, Ser175Gly and Leu236Arg.

25 8. A gene encoding the GFP protein according to either Item 1 or Item 2 as described above.

9. A gene encoding the BFP protein according to any of Items 3-7 as described above

This invention will be illustrated in detail

hereinbelow based on its embodiments. The abbreviations of nucleic acids and amino acids (one-letter and three-letter codes) as used in the present specification are set forth below.

5	(Nucleic Acids)	
	DNA	deoxyribonucleic acid
	A	Adenine
	C	Cytosine
	G	Guanine
10	T	Thymine
	(Amino Acids)	
	Ala (A)	Alanine
	Arg (R)	Arginine
	Asn (N)	Asparagine
15	Asp (D)	Aspartic acid
	Cys (C)	Cysteine
	Gln (Q)	Glutamine
	Glu (E)	Glutamic acid
	Gly (G)	Glycine
20	His (H)	Histidine
	Ile (I)	Isoleucine
	Leu (L)	Leucine
	Lys (K)	Lysine
	Met (M)	Methionine
25	Phe (F)	Phenylalanine
	Pro (P)	Proline

Ser (S)	Serine
Thr (T)	Threonine
Trp (W)	Tryptophan
Tyr (Y)	Tyrosine
5 Val (V)	Valine

BRIEF DESCRIPTION OF THE DRAWINGS

The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Patent 10 and Trademark Office upon request and payment of the necessary fee.

FIG. 1 is an electrophoresis photograph obtained when *E. coli* harboring each plasmid was induced by IPTG and its protein was subjected to SDS-PAGE, where 15 Lanes 1, 4, and 7 show the results of electrophoresis of 50 μ l equivalents of the *E. coli* culture media and Lanes 2, 3, 5, 6, 8, and 9 show those of 50 μ l equivalents.

FIG. 2 is a photograph showing the fluorescence 20 emitted when the *E. coli* harboring each plasmid was streaked on a plate, and after culturing at 37 °C overnight, it was irradiated with UV at a long wavelength. "1" indicates empty vector(pQE30), "2" indicates original GFP(pQE101). "3" indicates improved GFP(F64L/V163A/S175G)(pQE105). "4" indicates original BFP(pQE201). "5" indicates improved 25

BFP(F64L/L236R)(pQE202). "6" indicates improved
BFP(F64L/V163A/S175G/L236R)(pQE205).

FIG. 3 is an electrophoresis photograph showing
the results obtained when CHO cells, after
5 transfection with each plasmid, were cultured at
37 °C or at 30 °C, and the culture was subjected to
SDS-PAGE followed by transfer onto a nitrocellulose
membrane and western blotting with an anti-GFP
antibody. Here, the arrow indicates GFP or BFP.

10 FIGS. 4A and 4B are fluorescence photographs
showing the effects associated with the improved type
of GFP(B) with the original type of GFP(A).

15 FIGS. 4C and 4D are fluorescence photographs
showing the effects associated with the improved type
of BFP(D) with the original type of BFP(C).

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Novel GFP or BFP proteins according to this
invention are those obtained by introducing certain
mutations to parts of the amino acid sequences for
20 the wild types of GFP and BFP, and exhibit improved
fluorescence characteristics and thermal stability.
Therefore, this invention embraces proteins having at
least such amino acid sequences insofar as they
exhibit the improved fluorescence characteristics and
25 thermal stability based on the novel GFP or BFP
proteins according to the invention. Namely, in the

cases where cells of a variety of origins are used as will be in use in the Examples below, the invention also embraces proteins to which a variety of amino acid sequences other than the aforementioned 5 amino acid sequences are appended at their N- or C- termini and which exhibit the improved fluorescence characteristics and thermal stability based on the novel GFP or BFP proteins according to the invention.

Moreover, this invention provides genes encoding 10 such novel proteins or proteins containing them within parts thereof.

There are no particular limitations to methods for obtaining the novel GFPs or BFPs according to this invention, and methods for artificially 15 obtaining them by means of chemical syntheses and methods for obtaining them according to standard genetic engineering are possible. The latter methods are made possible through the genetic engineering techniques in which suitable vectors conventionally known and means for introducing mutations are 20 combined. Concretely, the following procedure is preferred.

Specifically, the procedure comprises the steps of: (1) starting with a known GFP or BFP protein to 25 be improved and introducing a gene encoding said protein into a suitable vector; (2) introducing

mutations into said gene selectively or randomly according to known methods; and (3) selecting desirable mutants on the basis of the fluorescence intensities and temperature-dependence, among others, 5 of the resultant GFP or BFP mutants.

The Contents of Application No.026418/1998, filed on January 23, 1998 in Japan is hereby incorporated by reference.

10 The above-mentioned procedure will be hereinbelow illustrated in detail by way of examples; however, this invention is not to be limited to these specific examples.

EXAMPLES

15 (I) The genetic engineering techniques as used in the present examples will be illustrated in the following.

1. Vector Construction

In this invention, a DNA portion encoding GFP of pGFP-C1 vector (available from Clontech Inc.) was 20 replaced by a DNA of GFP derived from phGFP-S65T (available from Clontech Inc.), which served as a basic plasmid (hereinafter referred to as "phGFP(101)-C1"). The vector is meant for expression in mammalian cells and its full base sequence 25 including the vector part is known in the art. The corresponding amino acid sequence is set forth below.

REPEATED SEQUENCES

	Met Val Ser Lys Gly Glu Glu Leu Phe, Thr Gly Val Val Pro Ile Leu Val			
1	5	10	15	
	Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu			
20	25	30		
5	Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys			
	35	40	45	
	Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe			
	50	55	60	
	Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln			
10	65	70	75	80
	His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg			
	85	90	95	
	Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val			
	100	105	110	
15	Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile			
	115	120	125	
	Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn			
	130	135	140	
	Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly			
20	145	150	155	160
	Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val			
	165	170	175	
	Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro			
	180	185	190	
25	Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser			
	195	200	205	

Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val

210 215 230

Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys

225 230 235 238

5

Here, the protein encoded by phGFP-S65T as described above is compared with that of a wild type derived from jellyfish: (i) an amino acid (valine) has been inserted between methionine, which is amino acid number 1 of the amino acid sequence, and serine, which is amino acid number 2; (ii) serine, which is amino acid number 65, has been further mutated to threonine; and (iii) histidine, which is amino acid number 231, has been mutated to leucine. These are respectively underlined in the amino acid sequence as described above. Thus for example, the amino acid number 65 threonine becomes number 66 in reality, but amino acid sequence numbers corresponding to those of the wild type are employed for the amino acid numbers connected with mutation, in accordance with general rules. In other words, the amino acid numbers for the amino acid sequence of the wild type derived from jellyfish (amino acid numbers 1 through 238) are to be used. The extra valine as described above is construed as having been inserted between amino acid number 1 and amino acid number 2, and no number is

then designated therefor. In practice, such an addition of valine has been used as a working example to illustrate the embodiments of this invention and it is not the essential amino acid sequence of this invention. Accordingly, in the explanation that follows the presence (or the absence) of the valine addition will not affect the scope of the invention.

Furthermore, methods for introducing specific mutations are not particularly limited, and for example, the method of introduction used in the examples of this invention as described below is feasible. Specifically, a DNA region encoding GFP was cut out from the above-mentioned phGFP(101)-Cl with HindIII, and it was inserted into the HindIII site of a pUC18 vector or a pQE30 vector (Qiagen) to thereby prepare pUCGFP(101) or pQEGFP(101). Here, the pQE30 vector was meant for expression in *E. coli*.

Employing the resultant pUCGFP(101), pUCBFP(101) into which the mutations of T65S, Y66H, and Y145F had been introduced by the site-directed mutation introduction method as described below was prepared.

Here, through said mutation the amino acid number 65 Ser that was introduced by the above-mentioned mutation (T65S) proved to be identical with the wild type site.

Further, a DNA encoding BFP was cut out from the

obtained pUCBFP(201) by digestion with EcoRI/XhoI and it was cloned into the EcoRI/XhoI site of Bluescript II KS(-) (Stratagene) to thereby prepare blueBFP(201).

Furthermore, a DNA region encoding BFP was cut
5 out from the obtained pUCBFP(201) by digestion with HindIII and it was inserted into the HindIII site of a pQE30 vector to thereby prepare pQE-BFP(201). On the other hand, phBFP(201)-Cl was prepared by replacing the GFP coding region of the phGFP(101)-Cl
10 vector with the above-mentioned DNA in like manner.

2. Mutagenic Polymerase Chain Reaction (hereinafter referred to as "PCR")

Moreover, methods for randomly introducing mutations are not particularly limited, and Mutagenic PCR as described below can preferably be used in this invention. The Mutagenic PCR can be carried out according to methods known in the art. (C. W. Dieffenbach, ed. PCR PRIMER, A Laboratory Manual (Cold Spring Harbor Laboratory Press) (1995) pp. 583-
15 588.) Concretely, the following conditions were
20 employed in the examples.

About 50 ng of Plasmid BlueBFP(201) was added to 10xmutagenic PCR buffer (70 mM MgCl₂, 500 mM KCl, and 100 mM Tris-HCl, pH 8.3 at 25 °C; 0.1% (w/v) gelatin)
25 10 μl, 10xdNTP (2 mM dGTP, 2 mM dATP, 10 mM dCTP, and 10 mM dTTP) 10 μl, 10 pmol/μl primer (23mer

M13Universal primer and M13Reverse primer) 3 μ l, and H₂O 62 μ l, and mixed. Subsequently, 10 μ l of 5 mM MnCl₂ was added and mixed, and 1 μ l of Taq Polymerase (Takara) was added to conduct PCR (PC-700 available from ASTEC Inc. was used). The PCR was conducted in three tubes under the following conditions: 25 cycles at 94 °C for 1 min, 30 cycles at 45 °C for 1 min, and 35 cycles at 72 °C for 1 min, respectively.

After the respective reaction solutions were combined and treated with chloroform twice, a DNA fragment encoding the amplified BFP was recovered by carrying out electrophoresis on a 1% agarose gel after digestion with BamHI and XhoI and it was inserted into the BamHI and SalI sites of pQE30 (Qiagen Inc.).

Transformation was performed on *E. coli* JM109, and inoculation was done in a LB medium containing carbenicillin to incubate JM109 at 37 °C for 16 h. Subsequently, the incubated product was allowed to stand at room temperature for 24 h. The *E. coli* colonies that resulted on a plate were irradiated with UV (Funakoshi UV Transilluminator FTI-201 UV 365 nm) from the top side of the plate for 1 h, and colonies emitting sufficient illumination visually after irradiation were selected: ten colonies were obtained in the example.

Sequence determination was performed on the selected plasmids. With respect to the mutant having mutations within its coding region that appeared meaningful, the coding region was cut out with Hind3
5 and was inserted into the HindIII site of pQE30, and thereafter, this was cut out with SalI/BglII and replaced by the corresponding portion of pQEBFP to bring the cloning site of the vector into conformity with pQEBFP(201): in the present examples the one prepared from Mutant 10 was designated pQEBFP (202).
10

3. Construction of Mutant GFP/BFP by the Site-Directed Mutation Introduction Method

The site-directed mutation introduction methods are not particularly limited, and for example, the protocol for a Quick Change Kit from Stratagene Inc.
15 was followed. The oligonucleotides shown in Table 2 below were used as primers and the plasmid (about 0.03 μ g) obtained by subcloning GFP or BFPcDNA into the HindIII site of a pUC18 or pQE30 vector was used
20 as a template. The concrete PCR conditions are preferably as follows: 16 cycles at 95 °C for 30 sec, 55 °C for 1 min, and 68 °C for 10 min.

TABLE 2

	oligo no.	sequence
	1F	TCGTGACCACCTTCTCCCACGGCCTGCA
5	1R	TGCACGCCGTGGGAGAAAGGTGGTCACGA
	2F	GCTGGAGTACAACCTAACACAGCCACAACG
	2R	CGTTGTGGCTGTTGAAGTTGTACTCCAGC
	3F	CCTCGTGACCACCCCTCTCCCACGGCGTG
	3R	CACGCCGTGGGAGAGGGTGGTCACGAGG
10	4F	CCTCGTGACCACCCCTCACCTACGGCGTG
	4R	CACGCCGTAGGTGAGGGTGGTCACGAGG
	5F	GAACGGCATCAAGGCCAACTTCAAGATCC
	5R	GGATCTTGAAGTTGGCCTTGATGCCGTTTC
	6F	CATCGAGGACGGCGGCGTGCAGCTCGCC
15	6R	GGCGAGCTGCACGCCGCCGTCCCTCGATG

TABLE 3

	GFP or BFP used as template	oligo no. used in the introduction of mutation	GFP mutant or BFP mutant after mutation-introduction
5	pUCGFP(101)	1F+1R	pUCGFP101(+Y66H)
	pUCGFP101(+Y66H)	2F+2R	pUC(201)
	pQEGFP(101)	4F+4R	pQEGFP(103)
10	pQEBFP(201)	3F+3R	pQEBFP(203)
	pQEGFP(101)	5F+5R	pQEGFP101(+V163A)
	pQEGFP101(+V163A)	6F+6R	pQEGFP(104)
	pQEBFP(201)	5F+5R	pQEBFP201(+V163A)
	pQEBFP201(+V163A)	6F+6R	pQEBFP(204)
15	pQEGFP(104)	4F+4R	pQEGFP(105)
	pQEBFP(202)	5F+5R	pQEBFP202(+V163A)
	pQEBFP202(+V163R)	6F+6R	pQEBFP(205)

20 Sequence determination of the resulting plasmids was conducted and it was verified that the desired mutations were contained in the plasmids.

25 In the examples of this invention, GFPs were designated as 101-105 and BFP were designated as 201-205 for reasons of convenience to place a variety of mutants as obtained in good order. Table 4 below

thus summarizes the mutations introduced. Although not shown in the table, GFP 101-105 all contain the mutations of Ser65Thr and His231Leu.

5

TABLE 4

GFP		
101	none	
103	Phe64Leu	
10	104	Val163Ala, Ser175Gly
	105	Phe64Leu, Val163Ala, Ser175Gly
<hr/>		
BFP (as for BFP, the two mutations, Y66H and Y145F, have been introduced into the sequence for GFP which serves as a basis)		
15	201	Y66H, Y145F:
	202	Y66H, Y145F: Phe64Leu, Leu236Arg
	203	Y66H, Y145F: Phe64Leu
	204	Y66H, Y145F: Val163Ala, Ser175Gly
	205	Y66H, Y145F: Phe64Leu, Val163Ala, Ser175Gly, Leu236Arg
20	<hr/>	

4. Determination of the Quantities of Expression for BFP Mutants

Determination of the quantities of expression for the BFP mutants obtained is not particularly limited, but a comparison of the quantities of their

expression in *E. coli* by means of SDS-PAGE is preferable. Concretely, an overnight culture of *E. coli* into which each expression vector of pQE30 (empty vector), pQE^BF(201), and pQE^BFP(202) had been introduced was diluted to 1/50 and it was grown in 3 ml of 2xYT carbenicillin medium at 37 °C for 3 h. IPTG was added to each sample to give its final concentration of 0.24 mg/ml, and the induction of a BFP protein was performed by further culturing the sample for 2.5 h.

An aliquot (100 µl) was taken out from each sample and centrifuged, and precipitates were dissolved in a sample buffer. For each sample, 1.3 ml of *E. coli* was centrifuged at 10,000 rpm for 1 min and precipitates were suspended in 260µl of PBS(-). This suspension was frozen and thawed at -80 °C for 10 min, and was subjected to ultrasonic treatment (Elma Transonic ultrasonic washer 460/H). Subsequently, it was centrifuged at 15,000 rpm for 5 min to separate soluble proteins from insoluble fractions containing the inclusion body. These were subjected to SDS-PAGE in quantities that correspond to 50µl cultures of *E. coli* and were stained with Coomassie Brilliant Blue.

25 5. Comparison of Brightness of *E. coli* Cells Having a Variety of GFPs and BFPs Introduced

JM109 was transformed with each of pQE30 (empty vector), pQEGFP(101), pQEGFP(105), pQE-BFP(201), pQE-BFP(202), and pQE-BFP(205), and it was streaked on a LB agar medium containing carbenicillin. After 5 incubation at 37 °C for 24 h, the upper lid was removed and the plate was turned upside down and irradiated with UV (Funakoshi UV Transilluminator FTI-201 UV 365 nm to have photographs taken.

10 6. Transfection of GFP and BFP Mutant cDNAs into CHO Cells by the Calcium Phosphate Method and Fluorescence Measurements

A. Transfection

Coding regions were cut out from the pQE vectors containing the genes of GFP and BFP mutants that had 15 been prepared by the site-directed mutation introduction method, and the corresponding portions of phGFP(101)-Cl vectors were replaced by them; thus, phGFP(103-105)-Cl and phBFP(202-205)-Cl were prepared.

Unless otherwise so stated, CHO-K1 cells were 20 grown in a F12+10% FBS medium in 5% CO₂ at 37 °C. The cells (1x10⁵) were inoculated into a 6-cm dish, and on the following day, their transfection was conducted in two dishes as a pair by the calcium phosphate method. (C. Chen and H. Okayama Mol. Cell. Biol. 7: 2745-2752 (1987).) After transfection, the 25 one dish was incubated at 37 °C and the other at

DEPARTMENT OF GENETICS

30 °C for 24 h. The transfected CHO cells were washed with 1xPBS(-) three times, and they were dissolved in 1 ml of 10 mMTris-HCl (pH 7.4) containing 1% Triton X-100 and recovered in an Eppendorf tube. A supernatant (0.5 ml) from centrifugation at 3,000 rpm for 5 min was diluted 4-fold with the same buffer and fluorescence measurement was performed. Here, a pUcD2SRαMCS vector (empty vector) was transfected and used as a blank. A Hitachi F-2000 type fluorophotometer was used in the fluorescence measurement. In the measurement of GFPs, fluorescence was scanned between 460 nm and 600 nm at an excitation wavelength of 460 nm to measure the maximal value in the vicinity of the fluorescence wavelength of 510 nm. In the measurement of BFPs, fluorescence was scanned between 360 nm and 500 nm at an excitation wavelength of 360 nm to measure the maximal value in the vicinity of the fluorescence wavelength of 445 nm.

20 7. Western Blotting

The CHO cells were transfected with pUcD2SRαMCS (empty vector)(T. Tsukamoto et al. Nature Genet. 11: 395-401 (1995)), phGFP(101)-Cl, phGFP(105)-Cl, phBFP(201)-Cl, and phBFP(205)-Cl, respectively and grown at 37 °C and at 30 °C. Employing a sample prior to dilution as used in the fluorescence

measurement previously described (8 μ l), SDS-PAGE was performed on a 12% gel. With the use of a Horizonblot (ATTO Inc.), transfer was conducted onto a nitrocellulose membrane (Millipore Inc., HAHY394FO) under the conditions of 2 mA and 90 min per cm^2 .
5 After the membrane was taken out and washed with 1xPBS, it was immersed in 1% skim milk/PBS and shaken at room temperature for 30 min. After the membrane was washed with 1xPBS, it was immersed in 0.1% skim
10 milk/PBS containing an anti-GFP antibody (Clonetech Inc.) that had been diluted 2,000-fold and shaken at 4 °C overnight. The membrane was washed with 1xPBS for 5 min, and then with TPBS (0.05% Trion X-100/PBS) for 15 min three times. The membrane was immersed in
15 0.1% skim milk/PBS containing an anti-rabbit IgG antibody labeled with HRP (Amersham Inc.) that had been diluted 1,000-fold, and shaken at 4 °C for 1 h. The membrane was washed with 1xPBS for 5 min, and then with TPBS (0.05% Trion X-100/PBS) for 15 min
20 three times. The membrane was reacted with a chemiluminescence reagent (Amersham Inc. ECL) for 1 min, and then, was exposed to an X-ray film for 2 min.

(II) Amino Acid Sequences of Novel GFP and BFP

Mutants

25 1. Sequence Determination of BFP Mutants

Among the 10 mutants obtained, one mutant

(Mutant No. 10) proved that phenylalanine at amino acid number 64, which had been at the immediate N-terminal side of the chromophore, mutated into leucine.

With respect to this mutant clone, another mutation (L236R) had been introduced into its C-terminus (Table 1)

TABLE 1

10	mutant no.	mutation
1		L(CTT)1H(CAT)
2		D(GAT)7Y(TAT)
3		I(ATC)6T(ACC)
4		the multicloning site: 14bp deletion
15		from BamHI
5		the multicloning site: 24bp deletion
		from BamHI
6		I(ATC)6N(AAC)
7		L(CTT)4P(CCT), I(ATC)128G(GTC),
20		D(GAC)197A(GCC), S(AGC)202C(TGC)
8		L(CTT)4R(CGT)
9		M(ATG)1T(ACG), Y(TAC)39N(AAC), K(AAG)52E(GAG)
10		K(AAG)41K(AAA)silent, F(TTC)64L(CTC),
		L(CTG)236R(CGG)

With respect to this mutant, BFPcDNA was

subcloned into the same HindIII site as in pQE⁺BFP(201) for a comparison purpose to prepare pQE⁺BFP(202).

5 2. Comparison of the Quantities of Expression for BFP Mutants in *E. coli* by SDS-PAGE

IPTG was added to *E. coli* cultures harboring pQE⁺BFP(201) and pQE⁺BFP(202) and BFP proteins were allowed to express. When the *E. coli* cells were irradiated with UV, the *E. coli* harboring pQE⁺BFP(202) apparently exhibited stronger fluorescence. When the proteins from these *E. coli* were analyzed by SDS-PAGE, the production of the 31 kDa protein was recognized to almost similar degrees in both *E. coli* having the respective plasmids (FIG. 1, Lanes 4 and 7).

10 When the solubility of these BFPs was also studied, BFP(201) with weaker fluorescence was nearly insoluble (FIG. 1, Lanes 5 and 6), whereas BFP(202) was mostly recovered in the soluble portion (FIG. 1, Lanes 8 and 9).

15 3. Comparison of Fluorescence of *E. coli* Cells Having a Variety of GFPs and BFPs Introduced

GFPs and BFPs into which the mutations of V163A and S175G had been further introduced in addition to F64L were prepared (see Table 4).

20 In order to compare the intensities of fluorescence in *E. coli*, streaking was performed

using *E. coli* cells having an empty pQE30 vector or pQE30 vectors into which cDNAs of GFP101, GFP105, BFP201, BFP202, and BFP205 had been subcloned. The *E. coli* having the empty vector introduced was not luminous. The *E. coli* having BFP201 prior to its improvement subcloned, even when irradiated with UV, was hardly luminous. In contrast, the one into which 202 had been subcloned was brightly luminous in blue. Further, it could be ascertained that 205 was even more brightly luminous than was 202.

As for GFPs, green fluorescence was observed by the naked eye, and a distinctive difference in brightness was noted between 101 and 105 (FIG. 2).

6. Transfection of GFP and BFP Mutant cDNAs into CHO Cells and Fluorescence Measurements

Since very luminous GFPs and BFPs were obtained in *E. coli*, the comparison was made also in mammalian cells (CHO). The results from the fluorescence measurements of cell extracts that were already prepared under culturing at 37 °C and at 30 °C are summarized (Table 5).

TABLE 5

GFP or BFP	37 °C	30 °C
101	30.8	214.6
5 103	532.1	765.4
104	659.0	697.9
105	2991.1	868.7
201	14.3	166.7
202	304.6	188.6
10 203	331.3	210.9
204	330.9	265.9
205	901.5	287.7

15 The values shown in the table are those obtained by subtracting the value of the empty vector used as a blank from the values of fluorescence obtained. The blank values were 8.9 in the measurement of GFPs at 37 °C, 7.14 in the measurement at 30 °C, 64.3 in
20 the measurement of BFPs at 37 °C, and 50 in the measurement at 30 °C.

25 Table 6 shows relative values when the fluorescence intensity of GFP or BFP prior to its improvement after culturing at 37 °C is taken as 100, and it also makes comparisons in terms of ratio of fluorescence at 37 °C to that at 30 °C. From Table 6,

BFP(202) having the mutation as found by the Mutagenic PCR exhibited the fluorescence 21 times stronger at 37 °C. Further, BFP(202) had two mutations (F64L and L236R); however, BFP(203) having 5 only F64L exhibited a similar intensity of fluorescence to that of 202. This mutation is believed to have caused stronger fluorescence. Seventeen times stronger fluorescence was observed in GFP(103) having F64L.

On the other hand, BFP(204) and GFP(104), both of which had the mutations of V163A and S175G, were brighter 23 times and 21 times, respectively. GFP(105) and BFP(205) in which these mutations were combined with F64L mutation were brighter 97 times 10 and 63 times. In addition, when the ratios of fluorescence intensities at 37 °C to those at 30 °C are taken for comparison, either of 101 and 201 prior to its improvement was darker at 37 °C than at 30 °C. Those having F64L alone or the combination of V163A 15 and S175G showed increases in the ratio of fluorescence intensities at two temperatures, whereas it was found that the fluorescence at 37 °C was more than three times brighter with respect to GFP(105) and BFP(205) in which the mutations were combined 20 (Table 6).

TABLE 6

GFP or BFP	37 °C	37 °C/30 °C
101	100	0.14
5 103	1728	0.70
104	2140	0.94
105	9711	3.44
201	100	0.09
202	2130	1.62
10 203	2317	1.57
204	2314	1.24
205	6304	3.13

15 6. Examination of the Quantities of Expression in
Animal Cells by Means of Western Blotting

The CHO cells were transfected with pUCD2SRαMCS (empty vector), phGFP(101)-Cl, phGFP(105)-Cl, phBFP(201)-Cl, and phBFP(205)-Cl, respectively and 20 cultured at 37 °C and 30 °C. Employing an anti-GFP antibody for the cultured cells, the quantities of GFP or BFP proteins expressed were examined. About 30kD bands that were not recognized in the transfection of the empty vector (FIG. 3, Lanes 1 and 25 6) were detected.

In culturing at 30 °C, no distinctive difference

was noted between the content of GFP or BFP proteins expressed prior to the introduction of mutations and that after the introduction of mutations (Lanes 7-10). On the other hand, in culturing at 37 °C it was found 5 that the mutants (Lanes 3 and 5) clearly expressed the GFP and BFP proteins in larger quantities (FIG. 3, Lanes 2-5).

The effects associated with the improved BFP and GFP mutants according to this invention are 10 summarized below.

(1) The mutant type BFP(202) obtained by the Mutagenic PCR exhibits enhanced fluorescence as compared to BFP prior to the introduction of mutation in either *E. coli* cells or mammalian cells. In the 15 clone of said mutant BPF, phenylalanine at amino acid number 64 has mutated into leucine (F64L), and further, leucine (amino acid number 236 at the C-terminus) has mutated into arginine (L236R).

With respect to the mutant type BFP(203) having 20 only the mutation at amino acid number 64 as described above, a similar enhancement in fluorescence was also noted in mammalian cells. Therefore, it is F64L that is the responsible mutation for this mutant type BFP(202).

Such a mutation is presumed to involve a 25 mechanism similar to the fluorescence enhancement

reported for GFP. (T. -T. Yang et al. Nucleic Acids Res. 24: 4592-4593 (1996).)

(2) The quantities of expression of proteins and the production of soluble proteins were investigated:

5 (i) Although the content of proteins is the same based on the comparison of the quantities of expression of Mutant BFPs in *E. coli* (through SDS-PAGE), the proteins from the mutant type BFP(201) are mostly insoluble whereas soluble proteins have
10 increased in the mutant type BPF(202); and (ii) a large difference in brightness was also seen in *E. coli*. These results indicate that the mutant type BPF(201) cannot correctly occupy a higher-order structure such as the formation of a chromophore
15 whereas the mutant type BPF(202) tends to occupy a more correct higher-order structure with ease: the mechanism for the above-mentioned fluorescence enhancement is believed to be due to this.

(3) On the other hand, the results of western blotting in the mammalian cells show that the quantity of proteins from GFP or BFP itself has increased. Namely, it is thought that the protein can occupy a stabilized higher-order structure in the mammalian cells; or alternatively, proteolysis becomes slower than that prior to the improvement because the protein structure is stabilized.

(4) With the introduction of the F64L mutation having the characteristics as described above and other mutations, V163A and S175G, GFP and BFP proteins that have markedly improved characteristics 5 in the expression at 37 °C in addition to those as described above are obtained.

Accordingly, the improved types of GFPS and BFPS into which such mutations have been introduced are provided with the characteristics that will allow 10 them to be brightly luminous even at 37 °C, and they will enable observation in the mammalian cells where culturing is to be conducted at 37 °C. These improved types of GFPS and BFPS can be applied to cell biology as well as to many research areas. FIGS. 15 4(A) to (B) show the effects of this invention as described above.

From the invention thus described, it will be obvious that the invention may be varied in many ways. Such variations are not to be regarded as a 20 departure from the spirit and scope of the invention, and all such modifications as would be obvious to one skilled in the art are intended for inclusion within the scope of the following claims.

SEQUENCE LISTING

SEQ ID NO: 1

LENGTH: 238

TYPE: amino acid

5 TOPOLOGY: linear

MOLECULE TYPE: peptide

SEQUENCE DESCRIPTION

Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val

1 5 10 15

10 Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
35 40 45Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
15 50 55 60Ser His Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln
66 70 75 80His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 9520 Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
25 130 135 140

Phe Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly

145 150 155 160
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
5 180 185 190
Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
195 200 205
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 230
10 Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
225 230 235 238

SEQ ID NO: 2

LENGTH: 28

15 TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

SEQUENCE DESCRIPTION

20 TCGTGACCA CTTCTCCAC GGC GTGCA 28

SEQ ID NO: 3

LENGTH: 28

TYPE: nucleic acid

25 STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

SEQUENCE DESCRIPTION

TGCACGCCGT GGGAGAAGGT GGTACACGA 28

5 SEQ ID NO: 4

LENGTH: 29

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

10 MOLECULE TYPE: DNA

SEQUENCE DESCRIPTION

GCTGGAGTAC AACTTCAACA GCCACAACG 29

SEQ ID NO: 5

15 LENGTH: 29

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

20 SEQUENCE DESCRIPTION

CGTTGTGGCT GTTGAAGTTG TACTCCAGC 29

SEQ ID NO: 6

LENGTH: 28

25 TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION
CCTCGTGACC ACCCTCTCCC ACGGCGTG 28

5

SEQ ID NO: 7
LENGTH: 28
TYPE: nucleic acid
STRANDEDNESS: single

10 TOPOLOGY: linear

MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION
CACGCCGTGG GAGAGGGTGG TCACGAGG 28

15 SEQ ID NO: 8

LENGTH: 28
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

20 MOLECULE TYPE: DNA

SEQUENCE DESCRIPTION
CCTCGTGACC ACCCTCACCT ACGGCGTG 28

SEQ ID NO: 9

25 LENGTH: 28
TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

SEQUENCE DESCRIPTION

5 CACGCCGTAG GTGAGGGTGG TCACGAGG 28

SEQ ID NO: 10

LENGTH: 29

TYPE: nucleic acid

10 STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

SEQUENCE DESCRIPTION

GAACGGCATC AAGGCCAACT TCAAGATCC 29

15

SEQ ID NO: 11

LENGTH: 29

TYPE: nucleic acid

STRANDEDNESS: single

20 TOPOLOGY: linear

MOLECULE TYPE: DNA

SEQUENCE DESCRIPTION

GGATCTTGAA GTTGGCCTTG ATGCCGTTC 29

25 SEQ ID NO: 12

LENGTH: 28

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

5 SEQUENCE DESCRIPTION

CATCGAGGAC GGCGGCGTGC AGCTCGCC 28

SEQ ID NO: 13

LENGTH: 28

10 TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

SEQUENCE DESCRIPTION

15 GGCAGAGCTGC ACGCCGCCGT CCTCGATG 28

DRAFT DOCUMENT - CGS-I 98-02